MMP2 and MMP10 Polymorphisms Are Related to Steroid-Induced Osteonecrosis of the Femoral Head among Chinese Han Population
Table 4
Stratified analysis for association of MMP2 and MMP10 gene polymorphism with the clinical phenotypes of steroid-induced ONFH.
SNPs
Subgroups
Genotype(n)
Allele(%)
AA/AB/BB
p
OR
95% CI
p
rs470154(T/G)
Controls
3 / 60 / 245
Case-Unilateral
4 / 15 / 64
0.094
1.34
0.81
2.23
0.258
Case-Bilateral
5 / 52 / 146
0.250
1.50
1.04
2.18
0.031
Case-Stage II
3 / 11 / 50
0.130
1.28
0.72
2.26
0.401
Case-Stage III
5 / 34 / 87
0.015
1.76
1.17
2.67
0.007
Case-Stage IV
1 / 22 / 73
0.820
1.19
0.72
1.96
0.492
Case > 12 months
5 / 31 / 121
0.190
1.25
0.83
1.90
0.290
Case ≤ 12 months
4 / 36 / 89
0.074
1.71
1.13
2.59
0.010
rs243866 (A/G)
Controls
8 / 68 / 231
Case-Unilateral
0 / 10 / 73
0.013
0.40
0.20
0.80
0.007
Case-Bilateral
3 / 48 / 152
0.470
0.97
0.67
1.40
0.862
Case-Stage II
1 / 10 / 53
0.400
0.65
0.35
1.23
0.187
Case-Stage III
1 / 21 / 104
0.240
0.63
0.39
1.03
0.064
Case-Stage IV
1 / 27 / 68
0.240
1.12
0.71
1.77
0.620
Case > 12 months
2 / 32 / 123
0.470
0.82
0.54
1.24
0.341
Case ≤ 12 months
1 / 26 / 102
0.240
0.77
0.49
1.21
0.255
rs243864 (G/T)
Controls
8 / 70 / 230
Case-Unilateral
0 / 10 / 73
0.010
0.40
0.20
0.78
0.006
Case-Bilateral
3 / 48 / 152
0.500
0.95
0.66
1.36
0.764
Case-Stage II
1 / 10 / 53
0.360
0.64
0.34
1.20
0.163
Case-Stage III
1 / 21 / 104
0.200
0.62
0.38
1.01
0.051
Case-Stage IV
1 / 27 / 68
0.270
1.10
0.69
1.73
0.692
Case > 12 months
2 / 32 / 123
0.470
0.80
0.53
1.21
0.286
Case ≤ 12 months
1 / 26 / 102
0.230
0.75
0.48
1.18
0.213
rs865094 (G/A)
Controls
22 / 120 / 166
Case-Unilateral
8 / 44 / 31
0.029
1.56
1.08
2.24
0.016
Case-Bilateral
9 / 88 /106
0.430
0.97
0.73
1.29
0.855
Case-Stage II
4 / 30 / 30
0.500
1.16
0.77
1.77
0.478
Case-Stage III
9 / 58 / 59
0.780
1.19
0.86
1.64
0.290
Case-Stage IV
4 / 92 / 48
0.370
1.02
0.71
1.47
0.900
Case > 12 months
9 / 70 / 78
0.750
1.07
0.79
1.45
0.649
Case ≤ 12 months
8 / 62 / 59
0.240
1.19
0.87
1.65
0.277
rs11646643 (G/A)
Controls
11 / 104 / 193
Case-Unilateral
1 / 18 / 64
0.062
0.53
0.32
0.88
0.014
Case-Bilateral
5 / 70 /127
0.320
0.96
0.70
1.31
0.800
Case-Stage II
2 / 22 / 40
0.640
0.99
0.62
1.59
0.971
Case-Stage III
2 / 38 / 86
0.360
0.78
0.53
1.14
0.200
Case-Stage IV
2 / 28 / 65
0.430
0.79
0.51
1.21
0.273
Case > 12 months
4 / 44 / 108
0.370
0.78
0.54
1.11
0.166
Case ≤ 12 months
2 / 44 / 83
0.320
0.89
0.61
1.29
0.532
rs2241146 (A/G)
Controls
12 / 107 / 188
Case-Unilateral
10 / 30 / 43
0.038
1.59
1.08
2.33
0.017
Case-Bilateral
13 / 58 / 132
0.230
0.96
0.71
1.31
0.804
Case-Stage II
6 / 14 / 44
0.076
0.94
0.59
1.51
0.797
Case-Stage III
7 / 44 / 75
0.650
1.10
0.78
1.57
0.587
Case-Stage IV
10 / 30 / 56
0.078
1.30
0.89
1.89
0.173
Case > 12 months
17 / 51 / 89
0.013
1.37
1.00
1.88
0.050
Case ≤ 12 months
6 / 37 / 86
0.710
0.86
0.60
1.25
0.435
rs9928731 (T/C)
Controls
63 / 166 / 78
Case-Unilateral
17 / 43 / 23
0.970
0.95
0.68
1.35
0.789
Case-Bilateral
47 / 107 / 49
0.860
1.08
0.84
1.39
0.542
Case-Stage II
15 / 29 / 20
0.550
0.94
0.64
1.38
0.763
Case-Stage III
28 / 72 / 26
0.600
1.14
0.85
1.53
0.387
Case-Stage IV
21 / 49 / 26
0.980
0.99
0.72
1.37
0.969
Case > 12 months
27 / 88 / 42
0.670
0.91
0.69
1.20
0.500
Case ≤ 12 months
37 / 62 / 30
0.270
1.23
0.92
1.64
0.164
P<0.05 indicates statistical significance. P values were calculated by Wald test adjusted for age and gender. P values were calculated by Pearson Chi-squared test.
